Bruker BioSciences to Present at Bear Stearns Healthcare Conference

   Live Webcast on September 12th at 9:30 AM Eastern Time from New
    York

   Bruker BioSciences Corporation (Nasdaq: BRKR) today announced that
it will join other leading healthcare and life sciences companies in
presenting at the Bear Stearns 18th Annual Healthcare Conference
taking place September 12 and 13 in New York. Bruker BioSciences
Corporation's Chairman, President and CEO, Frank H. Laukien, Ph.D.,
will present an overview of the Company, including an update on recent
developments and expectations. He will be accompanied by Chief
Financial Officer William J. Knight.
   Dr. Laukien's presentation will be webcast live at 9:30 AM Eastern
Time on Monday, September 12 from the Grand Hyatt hotel in New York.
The webcast can be accessed on Bruker BioSciences' website at
www.bruker-biosciences.com with playback available until October 12.

   ABOUT BRUKER BIOSCIENCES

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker AXS
Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and
provider of life science and advanced materials research tools based
on X-ray technology. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry.
For more information, please visit www.bruker-biosciences.com

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-K for the year ended December 31,
2004 our most recent quarterly reports on Form 10-Q, our current
reports on Form 8-K and the joint proxy statement/prospectus filed in
connection with the merger with Bruker AXS. We disclaim any intent or
obligation to update these forward-looking statements.